Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

The successful launch of Ebglyss® in the first markets in Europe generated €20.4 MM in the initial nine months of 2024, representing a 34% sales increase quarter-on-quarter. The potential of ...

The launch of Almirall’s eczema treatment, Ebglyss (lebrikizumab), generated $22 million in sales across initial European markets, while Ilumetri (tildrakizumab) for psoriasis saw sales rise 24.8% ...

Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Key pipeline milestones included U.S. approval of Ebglyss for atopic dermatitis and Kisunla for early symptomatic Alzheimer’s disease. The company plans to submit a supplemental application to ...

Eli Lilly announced positive results from its Phase 3b study of Ebglyss, which focused on patients with moderate-to-severe ...

Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

Headquartered in Indianapolis, Indiana, Eli Lilly and Company (LLY) is a leading biopharmaceutical firm with a market cap of ...